Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells

Zhang, Y and Huang, Y and Zhang, P and Gao, X and Gibbs, RB and Li, S (2012) Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells. International Journal of Nanomedicine, 7. 4473 - 4485. ISSN 1176-9114

Available under License : See the attached license file.

Download (2MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Background: The sigma-2 receptor is an attractive target for tumor imaging and targeted therapy because it is overexpressed in multiple types of solid tumors, including prostate cancer, breast cancer, and lung cancer. SV119 is a synthetic small molecule that binds to sigma-2 receptors with high affinity and specificity. This study investigates the utility of SV119 in mediating the selective targeting of liposomal vectors in various types of cancer cells. Methods: SV119 was covalently linked with polyethylene glycol-dioleyl amido aspartic acid conjugate (PEG-DOA) to generate a novel functional lipid, SV119-PEG-DOA. This lipid was utilized for the preparation of targeted liposomes to enhance their uptake by cancer cells. Liposomes with various SV119 densities (0, 1, 3, and 5 mole%) were prepared and their cellular uptake was investigated in several tumor cell lines. In addition, doxorubicin (DOX) was loaded into the targeted and unmodified liposomes, and the cytotoxic effect on the DU-145 cells was evaluated by MTT assay. Results: Liposomes with or without SV119-PEG-DOA both have a mean diameter of approximately 90 nm and a neutral charge. The incorporation of SV119-PEG-DOA significantly increased the cellular uptake of liposomes by the DU-145, PC-3, A549, 201T, and MCF-7 tumor cells, which was shown by fluorescence microscopy and the quantitative measurement of fluorescence intensity. In contrast, the incorporation of SV119 did not increase the uptake of liposomes by the normal BEAS-2B cells. In a time course study, the uptake of SV119 liposomes by DU-145 cells was also significantly higher at each time point compared to the unmodified liposomes. Furthermore, the DOX-loaded SV119 liposomes showed significantly higher cytotoxicity to DU-145 cells compared to the DOX-loaded unmodified liposomes. Conclusion: SV119 liposomes were developed for targeted drug delivery to cancer cells. The targeting efficiency and specificity of SV119 liposomes to cancer cells was demonstrated in vitro. The results of this study suggest that SV119-modified liposomes might be a promising drug carrier for tumor-targeted delivery. © 2012 Zhang et al, publisher and licensee Dove Medical Press Ltd.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Zhang, Y
Huang, Yyih34@pitt.eduYIH34
Zhang, Ppez11@pitt.eduPEZ11
Gao, X
Gibbs, RBgibbsr@pitt.eduGIBBSR
Li, Ssol4@pitt.eduSOL4
Date: 5 December 2012
Date Type: Publication
Journal or Publication Title: International Journal of Nanomedicine
Volume: 7
Page Range: 4473 - 4485
DOI or Unique Handle: 10.2147/ijn.s31981
Schools and Programs: School of Medicine > Pharmacology and Chemical Biology
Refereed: Yes
ISSN: 1176-9114
Date Deposited: 03 Dec 2012 22:25
Last Modified: 04 Feb 2019 15:58


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item